Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock

Zevra Therapeutics (NASDAQ:ZVRA) had its target price increased by equities researchers at Cantor Fitzgerald from $24.00 to $34.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price indicates a potential upside of 202.90% from the stock’s current price.

A number of other equities analysts have also commented on the stock. Weiss Ratings lowered shares of Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd. BTIG Research began coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $23.00 target price for the company. Wall Street Zen downgraded Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Guggenheim increased their price target on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Zevra Therapeutics has an average rating of “Moderate Buy” and an average price target of $25.00.

Zevra Therapeutics Stock Up 5.8%

Zevra Therapeutics stock traded up $0.62 during mid-day trading on Monday, hitting $11.23. 210,190 shares of the company were exchanged, compared to its average volume of 1,212,507. The company has a market capitalization of $663.57 million, a PE ratio of 5.61 and a beta of 0.91. The business has a fifty day moving average of $10.32 and a 200 day moving average of $9.37. Zevra Therapeutics has a 1-year low of $7.16 and a 1-year high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.06 by $0.12. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. The company had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Research analysts expect that Zevra Therapeutics will post 0.56 earnings per share for the current year.

Institutional Trading of Zevra Therapeutics

Hedge funds have recently modified their holdings of the stock. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Zevra Therapeutics in the fourth quarter valued at approximately $53,000. Russell Investments Group Ltd. boosted its position in Zevra Therapeutics by 235.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after buying an additional 4,475 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after buying an additional 8,552 shares during the last quarter. Creative Planning acquired a new stake in shares of Zevra Therapeutics in the 2nd quarter valued at $92,000. Finally, Quarry LP acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter valued at $103,000. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.